 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...207208209210211212213214215216217...235236» |
- |||||| Vectibix (panitumumab) / Amgen
Biomarker, Enrollment open: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - Jun 9, 2015
P3, N=800, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting
- ||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Jun 9, 2015
P2, N=57, Active, not recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- DC-CIK / Hornetcorn Biotech
Enrollment closed, Trial primary completion date: Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer (clinicaltrials.gov) - Jun 6, 2015
P2, N=40, Active, not recruiting, Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> May 2018
- DC-CIK / Hornetcorn Biotech
Enrollment closed, Trial primary completion date, Surgery: Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer (clinicaltrials.gov) - Jun 6, 2015
P2, N=60, Active, not recruiting, Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> May 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 2, 2015
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017 Suspended --> Recruiting
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment change, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 1, 2015
P1, N=225, Recruiting, Sponsor: Genentech, Inc.
Suspended --> Recruiting N=180 --> 225
- | HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
Enrollment open: Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Jun 1, 2015
P2, N=48, Recruiting, Sponsor: NewLink Genetics Corporation
N=180 --> 225 Not yet recruiting --> Recruiting
- |||| Biomarker, Enrollment open, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jun 1, 2015
P2, N=610, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> Mar 2019
- |||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Enrollment open, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 1, 2015
P2, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> Mar 2019 Active, not recruiting --> Recruiting
- Enrollment change, Metastases: FOLFIRINOX in Patients With Inoperable Pancreatic Cancer (clinicaltrials.gov) - May 29, 2015
P2, N=5, Terminated, Sponsor: University of Oklahoma
Active, not recruiting --> Recruiting N=25 --> 5
- | BMS-986142 / BMS
New P1 trial: Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients (clinicaltrials.gov) - May 29, 2015
P1, N=24, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Mekinist (trametinib) / Novartis, BeiGene
Enrollment closed, Surgery, Metastases: SWOG-S1310: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (clinicaltrials.gov) - May 29, 2015
P2, N=89, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=25 --> 5 Suspended --> Active, not recruiting
- New P2 trial: Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma (clinicaltrials.gov) - May 28, 2015
P2, N=30, Not yet recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- | Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - May 27, 2015
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting N=2433 --> 3610 | Trial primary completion date: Feb 2015 --> Aug 2015
- |||||||||| Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P3 trial: Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis (clinicaltrials.gov) - May 26, 2015
P3, N=360, Not yet recruiting, Sponsor: Zhejiang University
- ||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: HR Combined With FOLFOX4 for HCC With PVTT (clinicaltrials.gov) - May 26, 2015
P2, N=51, Active, not recruiting, Sponsor: Sun Yat-sen University
- | suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
New P1 trial, Metastases: A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 26, 2015
P1, N=22, Not yet recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- Avastin (bevacizumab) / Roche, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Enrollment change, Combination therapy: FAST: FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma (clinicaltrials.gov) - May 22, 2015
P2/3, N=0, Withdrawn, Sponsor: Sirtex Medical
N=2433 --> 3610 | Trial primary completion date: Feb 2015 --> Aug 2015 N=30 --> 0
- || telisotuzumab (h224G11) / AbbVie
Enrollment closed, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - May 22, 2015
P1, N=124, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=30 --> 0 Recruiting --> Active, not recruiting
- | imalumab (BAX069) / Takeda, Vectibix (panitumumab) / Amgen
New P2 trial: Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 20, 2015
P2, N=90, Not yet recruiting, Sponsor: Baxalta US Inc.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Metastases: SCI-101: Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China (clinicaltrials.gov) - May 19, 2015
P1/2, N=20, Completed, Sponsor: Shen Lin
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment open, Metastases: BCC-RAD-13: Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer (clinicaltrials.gov) - May 14, 2015
P2, N=28, Recruiting, Sponsor: James Graham Brown Cancer Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- | New P2 trial: Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial (clinicaltrials.gov) - May 12, 2015
P2, N=46, Not yet recruiting, Sponsor: Yonsei University
- |||||| onartuzumab (RG3638) / Roche
Enrollment open, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - May 12, 2015
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - May 12, 2015
P2, N=132, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion, Enrollment change: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - May 12, 2015
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=50 --> 37
- Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy: Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis (clinicaltrials.gov) - May 8, 2015
P2, N=44, Not yet recruiting, Sponsor: Gachon University Gil Medical Center
- ||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 8, 2015
P2, N=92, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1 (clinicaltrials.gov) - May 7, 2015
P2, N=96, Recruiting, Sponsor: Fundaci
Active, not recruiting --> Completed | N=50 --> 37 Trial primary completion date: Jul 2014 --> Jul 2018
- ||||| thioguanine / Generic mfg.
Enrollment closed: Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 7, 2015
P3, N=1076, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Jul 2014 --> Jul 2018 Completed --> Active, not recruiting
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Metastases: HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC (clinicaltrials.gov) - May 6, 2015
P2, N=0, Temporarily Not Available, Sponsor: Ming Zhao
- varlitinib (ASLAN001) / ASLAN Pharma
New P1 trial, Combination therapy: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (clinicaltrials.gov) - May 6, 2015
P1, N=18, Recruiting, Sponsor: National Cancer Centre, Singapore
- Xpovio (selinexor) / Karyopharm
Enrollment open, Metastases: SENTINEL: Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 6, 2015
P1, N=27, Recruiting, Sponsor: GSO Global Clinical Research BV
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| thioguanine / Generic mfg.
Trial primary completion date: AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov) - May 4, 2015
P3, N=5872, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2015 --> Sep 2015
- Cyramza (ramucirumab) / Eli Lilly
Trial primary completion date, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - Apr 30, 2015
P1, N=9, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Apr 2015 --> Sep 2015 Trial primary completion date: Apr 2015 --> Sep 2015
- Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date: Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study) (clinicaltrials.gov) - Apr 30, 2015
P=N/A, N=430, Active, not recruiting, Sponsor: RWTH Aachen University
Trial primary completion date: Apr 2015 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> May 2015
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 29, 2015
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> May 2015 Trial primary completion date: Mar 2015 --> Oct 2015
- || Xpovio (selinexor) / Karyopharm
Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Apr 28, 2015
P1, N=251, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2015 --> Oct 2015 N=51 --> 251
- | leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors (clinicaltrials.gov) - Apr 28, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
N=51 --> 251 No longer recruiting --> Completed
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC (clinicaltrials.gov) - Apr 27, 2015
P2, N=28, Active, not recruiting, Sponsor: Sun Yat-sen University
- ||||| Stivarga (regorafenib) / Bayer
New P2 trial: Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX (clinicaltrials.gov) - Apr 25, 2015
P2, N=264, Recruiting, Sponsor: US Oncology Research
- ||| Xpovio (selinexor) / Karyopharm
New P1 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Apr 25, 2015
P1, N=251, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change, Trial primary completion date: Phase II Trial Evaluating OS With Therasphere (clinicaltrials.gov) - Apr 23, 2015
P2, N=9, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
No longer recruiting --> Completed N=58 --> 9 | Trial primary completion date: May 2015 --> Dec 2015
- Enrollment closed, Metastases: S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Apr 23, 2015
P2, N=213, Active, not recruiting, Sponsor: Southwest Oncology Group
N=58 --> 9 | Trial primary completion date: May 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- ||||| thioguanine / Generic mfg.
Trial initiation date: AALL0331: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 22, 2015
P3, N=5377, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Initiation date: Jan 2005 --> Apr 2005
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial: Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer (clinicaltrials.gov) - Apr 22, 2015
P2, N=56, Completed, Sponsor: The First People's Hospital of Changzhou
- conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Apr 20, 2015
P2, N=12, Active, not recruiting, Sponsor: Amgen
Initiation date: Jan 2005 --> Apr 2005 Trial primary completion date: Apr 2015 --> Dec 2015
- Avastin (bevacizumab) / Roche
New P2 trial: Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis (clinicaltrials.gov) - Apr 20, 2015
P2, N=50, Not yet recruiting, Sponsor: University of California, San Diego
- ||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 20, 2015
P2, N=80, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || pegilodecakin (LY3500518) / Eli Lilly
Trial primary completion date: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 19, 2015
P1, N=135, Recruiting, Sponsor: ARMO BioSciences
Trial primary completion date: Apr 2015 --> Dec 2015 Trial primary completion date: Dec 2014 --> Dec 2015